STOCK TITAN

Apyx Medical Corporation - APYX STOCK NEWS

Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.

Overview

Apyx Medical Corporation is an energy technology company distinguished by its innovative plasma‐based medical devices utilized in both the cosmetic and hospital surgical markets. The company develops, manufactures, and markets advanced energy solutions that provide surgeons with precise and controlled heat applications, addressing both tissue cutting and coagulation needs. Operating under a dual-segment framework, its services are divided into Advanced Energy and Original Equipment Manufacturing (OEM), each contributing uniquely to its overall market presence. Its technology portfolio, including the Renuvion and J-Plasma systems, leverages patented helium plasma technology and specialized waveforms, enabling high-performance surgical applications and reducing unintended tissue trauma.

Advanced Energy Solutions

The Advanced Energy segment of Apyx Medical Corporation centers on its core plasma-based technologies. These systems are designed to offer enhanced control during surgical and cosmetic procedures by delivering precise energy in the form of helium plasma. Surgeons in both cosmetic and hospital surgical environments benefit from these technologies through improved accuracy and reduced collateral tissue damage. The company has strategically engineered its products to support various applications, ranging from body contouring and soft tissue ablation to coagulation, positioning itself as a key player in the energy technology medical device industry. The integration of over 90 clinical documents demonstrates a consistent level of clinical validation and supports the efficacy and safety profiles of these advanced energy solutions.

OEM Manufacturing Capabilities

In addition to its Advanced Energy segment, Apyx Medical Corporation is also prominently involved in the Original Equipment Manufacturing (OEM) sector. By designing and producing electrosurgical generators and related accessories, the company not only markets its own devices but also partners with other leading medical device manufacturers. This dual approach enables Apyx to extend its technological expertise to a wider market, enhancing its revenue streams while fostering innovation across the medical device landscape. The OEM segment benefits from the company’s deep experience in developing unique waveform technologies and precision energy delivery, making it an indispensable partner in the creation of next-generation medical devices.

Technology and Innovation

The technological backbone of Apyx Medical Corporation lies in its pursuit of innovation within the energy technology sector. The company’s patented plasma-based systems, marketed under brands such as Renuvion and J-Plasma, are at the forefront of modern electrosurgical applications. These systems enable controlled energy delivery, allowing surgeons to work with enhanced precision and significantly reducing the risk of unintended tissue trauma. The controlled heat delivery mechanisms are particularly critical in cosmetic and reconstructive procedures, where precision is paramount. The company’s considerable investment in research and clinical studies underpins its commitment to technological excellence, providing a robust foundation for continuous improvements and product enhancements.

Market Position and Industry Impact

Apyx Medical Corporation occupies a distinct position within the broader energy technology and medical device sectors. With a reputation for developing innovative plasma-based surgical solutions, the company serves a diverse clientele including plastic surgeons, facial plastic surgeons, and cosmetic physicians. Its technologies are integral in procedures that demand high precision and minimal invasiveness. The advanced energy solutions not only address existing surgical challenges but also set new standards in terms of device performance and patient safety. This strategic positioning is further reinforced by the company’s OEM collaborations, which enable it to disseminate its expertise across various facets of the medical device industry. While navigating a competitive environment that includes both established and emerging players, Apyx distinguishes itself through its commitment to refining technological innovations and adhering to rigorous clinical standards.

Operational Excellence and Quality Assurance

Operational excellence is a core tenet of Apyx Medical Corporation’s business model. The company emphasizes rigorous quality control processes during the design, development, and manufacturing phases of its products. Such practices ensure that every device meets stringent safety and performance criteria, a crucial factor in the highly regulated medical device industry. Through continuous process improvements and quality management systems, the company maintains a robust operational framework that supports its long-term sustainability and reliability as a technology provider. This commitment to excellence enhances trust among healthcare professionals and institutional partners alike.

Clinical and Surgical Applications

The practical applications of Apyx Medical Corporation’s technologies span a wide range of clinical and surgical environments. In cosmetic surgery, the Renuvion system offers a transformative approach to body contouring by providing controlled energy delivery tailored for precision and minimal invasiveness. Similarly, the J-Plasma system is engineered to meet the rigorous demands of hospital surgical procedures, ensuring that surgeons can achieve effective tissue modification with enhanced safety. The integration of clinical evidence into its product development process further confirms the efficacy of these applications, thereby fortifying the company’s reputation in the clinical community. This dual-application strategy not only broadens the market reach but also underscores the versatility and adaptability of the company’s technological solutions.

Strategic Collaborations and Market Expansion

Apyx Medical Corporation’s strategic approach includes forging key partnerships within the medical device sector through OEM arrangements. These collaborations facilitate the integration of its advanced energy technologies into the broader ecosystem of medical devices, thereby driving market expansion. By leveraging the expertise of established industry partners, the company is able to refine its product offerings, gain new insights into market demands, and maintain a competitive edge. Such collaborations ensure that Apyx remains at the cutting edge of medical technology innovation, thereby continuously reinforcing its value proposition.

Expertise and Authoritativeness

The company’s extensive experience and technical expertise in the field of energy-based surgical solutions are evident in its comprehensive portfolio and the clinical validation of its products. With a heritage rooted in decades of research and innovation, Apyx Medical Corporation has developed a robust framework for understanding and addressing the complex challenges inherent in both cosmetic and surgical treatments. This depth of expertise is reflected in the strategic development and deployment of its technologies, which combine precision engineering with a clear understanding of clinical needs. The company’s ability to deliver solutions that optimize surgical outcomes while minimizing risks highlights its authoritative presence in the energy technology space.

Competitive Landscape and Differentiation

Within a competitive market populated by several established players, Apyx Medical Corporation differentiates itself through its unique blend of advanced energy technology and strategic OEM partnerships. Its focus on precision, safety, and controlled heat delivery distinguishes its product offerings from traditional electrosurgical instruments. The company’s approach to integrating clinical evidence with innovative technology ensures that its solutions are both effective and reliable. This differentiation is critical in an industry where technological nuances can significantly impact surgical outcomes and patient safety. By continually investing in research and maintaining rigorous quality standards, Apyx positions itself as a trusted provider of cutting-edge medical technologies.

Conclusion

In summary, Apyx Medical Corporation exemplifies the convergence of energy technology and advanced medical device manufacturing. Its dual-segment operation, spanning both advanced energy products and OEM manufacturing, enables the company to offer comprehensive solutions that address critical needs in cosmetic and surgical applications. Through its innovative plasma-based systems, the company delivers unmatched precision and safety, supported by an extensive body of clinical research and a commitment to operational excellence. As a respected contributor to the energy technology and medical device industries, Apyx continues to influence the standard of care in surgical procedures, making it a subject of ongoing interest for investors, healthcare professionals, and industry analysts alike.

Rhea-AI Summary
Apyx Medical Corporation (APYX) to release financial results for Q4 and FY 2023 on March 21st, with a conference call to discuss the outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
-
Rhea-AI Summary
Apyx Medical Corporation announces that its Renuvion technology will be featured in educational sessions at the American Academy of Cosmetic Surgery’s 40th Annual Scientific Meeting. Dr. Michael Kluska will present results of a clinical study showing fewer adverse events with Renuvion compared to a competing technology in liposuction and body contouring procedures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.48%
Tags
none
-
Rhea-AI Summary
Apyx Medical Corporation announced the publication of a peer-reviewed article in the Aesthetic Surgery Journal Open Forum, which evaluated the use of Renuvion for contracting subcutaneous soft tissue following liposuction in multiple areas of the body. The analysis of data from 483 patients found no new or increased risks for any area of the body compared to the use of liposuction alone. The study demonstrated Renuvion's impressive safety when used after liposuction, which led to securing FDA 510(k) clearance for the use of Renuvion APR Handpiece. The authors concluded that the use of Renuvion following liposuction for any particular area of the body demonstrated no new or increased risks compared to published data for patients having liposuction performed alone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.03%
Tags
none
Rhea-AI Summary
Apyx Medical Corporation (NASDAQ:APYX) reported preliminary revenue results for the fourth quarter and full year ended December 31, 2023. Total revenue for Q4 2023 was approximately $14.2 to $14.6 million, representing 13% to 16% year-over-year growth. Full year 2023 revenue was approximately $51.9 to $52.3 million, showing 17% to 18% year-over-year growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
none
-
Rhea-AI Summary
Apyx Medical Corporation (APYX) announced a new $45 million credit agreement with Perceptive Credit Holdings IV, LP, providing access to additional capital at more attractive terms. The facility includes senior, secured term loans, with an initial loan of $37.5 million fully drawn at closing. The agreement matures on November 8, 2028, with an initial loan of $37.5 million and a delayed draw loan of $7.5 million. The loans bear interest at a floating rate based on one-month SOFR, subject to a floor of 5.0%, plus 7.0%. The Perceptive Credit Agreement provides for 48 months of interest-only payments, with subsequent monthly payments of 3.0% of the outstanding balance. The obligations under the facility are secured by first priority liens on substantially all of the Company's assets. In connection with the initial loan, the Company issued Perceptive warrants to purchase up to 1,250,000 shares of its common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.29%
Tags
none
-
Rhea-AI Summary
Apyx Medical Corporation (NASDAQ:APYX) reported a 39% year-over-year increase in Q3 Advanced Energy sales, reaching $9.8 million. The Company also announced a new credit agreement and updated its financial expectations for the full year. The third quarter results showed a 31% year-over-year increase in total revenue to $12.0 million, with a net loss of $4.6 million. The updated guidance for 2023 includes a total revenue range of $53.0 million to $54.0 million, representing a 19% to 21% year-over-year growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.29%
Tags
Rhea-AI Summary
Apyx Medical Corporation (NASDAQ:APYX) announced its participation in upcoming investor conferences, including the Stephens Annual Investment Conference, Craig-Hallum 14th Annual Alpha Select Conference, and Piper Sandler 35th Annual Healthcare Conference. Management will engage in fireside chats and 1x1 meetings, with audio webcasts available for replay on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Apyx Medical Corporation will release its financial results for Q3 of fiscal year 2023 on November 9th. A conference call will be held to discuss the results and a webcast will be available. A telephonic replay will also be accessible.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.63%
Tags
-
Rhea-AI Summary
Apyx Medical Corporation reports Q2 2023 financial results, with total revenue of $13.6 million, up 32% YoY. Advanced Energy revenue increased 40% YoY to $11.7 million. Net loss attributable to stockholders decreased 82% YoY to $1.0 million. Company reaffirms financial guidance for full year 2023, expecting total revenue in the range of $59.0 million to $62.0 million, representing growth of approximately 33% to 39% YoY.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.1%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.93%
Tags

FAQ

What is the current stock price of Apyx Medical Corporation (APYX)?

The current stock price of Apyx Medical Corporation (APYX) is $1.25 as of April 1, 2025.

What is the market cap of Apyx Medical Corporation (APYX)?

The market cap of Apyx Medical Corporation (APYX) is approximately 47.8M.

What is Apyx Medical Corporation's core business?

Apyx Medical Corporation specializes in designing, manufacturing, and marketing plasma-based medical devices used in cosmetic and surgical procedures. The company's products provide precision energy delivery for tissue cutting, coagulation, and ablation.

How does Apyx generate revenue?

The company generates revenue through its Advanced Energy segment, which markets innovative plasma-based devices, and its OEM segment, which supplies electrosurgical equipment and related accessories to other medical device manufacturers.

What are the main technologies used by Apyx Medical Corporation?

Apyx utilizes patented plasma-based technologies, including helium plasma systems, in its Renuvion and J-Plasma product lines. These technologies enable controlled heat delivery for precise surgical and cosmetic applications.

Who are the primary customers of Apyx Medical Corporation?

The company's products are used by a diverse range of medical professionals, such as plastic surgeons, facial plastic surgeons, and general surgical teams, across cosmetic surgery centers and hospital surgical departments.

How does the company ensure the safety and efficacy of its products?

Apyx Medical Corporation maintains rigorous quality assurance and testing protocols during product design and manufacturing. Its systems are supported by extensive clinical documentation that validates their safety and performance.

What differentiates Apyx Medical Corporation from its competitors?

Apyx stands out due to its innovative use of plasma-based energy technologies and its dual-segment approach that includes both advanced energy systems and OEM manufacturing. This combination allows for a versatile and clinically validated product portfolio.

In what ways does the company support clinical applications?

The company's products are designed to offer precise control in surgical procedures, minimizing tissue trauma and enhancing outcomes. This is particularly beneficial in cosmetic and reconstructive surgeries where precision is critical.

What role do OEM partnerships play for Apyx Medical Corporation?

OEM partnerships enable Apyx to extend its technical expertise to a broader range of medical devices. By collaborating with other manufacturers, the company leverages its innovative technologies to enhance the overall performance of various medical systems.
Apyx Medical Corporation

Nasdaq:APYX

APYX Rankings

APYX Stock Data

47.81M
32.14M
14.56%
45.84%
0.37%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
CLEARWATER